<DOC>
	<DOCNO>NCT01551888</DOCNO>
	<brief_summary>The purpose Phase II study evaluate pharmacokinetics , safety , tolerability aclidinium/formoterol fix dose combination ( FDC 400/12 μg via Almirall Inhaler formoterol 12 μg via Foradil® Aerolizer® , administer twice daily five day patient moderate severe COPD .</brief_summary>
	<brief_title>Pharmacokinetic , Safety Tolerability Study Aclidinium/Formoterol Fixed Dose Combination Formoterol Patients With Moderate Severe Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Current former cigarette smoker cigarette smoke history least 10 packyears A diagnosis stable moderate severe COPD stable airway obstruction define Global Initiative Chronic Obstructive Lung Disease guideline stable airway obstruction . Patients hospitalize acute COPD exacerbation within three month prior Screening Any respiratory tract infection ( include upper respiratory tract ) COPD exacerbation six week Screening Patients clinically significant respiratory condition COPD Clinical history suggest patient asthma oppose COPD Chronic use oxygen therapy ≥ 15 hours/day Patients clinically significant cardiovascular condition Patients history hypersensitivity reaction inhale anticholinergic , beta2 agonist , sympathomimetic amine , inhale medication</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>COPD</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>Chronic Bronchitis</keyword>
	<keyword>Emphysema</keyword>
	<keyword>Airflow Obstruction , Chronic</keyword>
	<keyword>Chronic Airflow Obstruction</keyword>
	<keyword>Chronic Obstructive Airway Disease</keyword>
	<keyword>Chronic Obstructive Lung Disease</keyword>
</DOC>